$ATYR
aTyr Pharma Inc

2022 Q1 Form 10-Q Financial Statement

#000156459022019293 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.482M $2.690M
YoY Change 29.44% 3.86%
% of Gross Profit
Research & Development $8.896M $4.520M
YoY Change 96.81% 24.86%
% of Gross Profit
Depreciation & Amortization $81.00K $121.0K
YoY Change -33.06% -22.93%
% of Gross Profit
Operating Expenses $8.896M $7.200M
YoY Change 23.56% 16.02%
Operating Profit -$12.38M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $224.0K $47.00K
YoY Change 376.6% -142.73%
Pretax Income -$12.15M -$7.160M
YoY Change 69.75% -509.14%
Income Tax
% Of Pretax Income
Net Earnings -$12.20M -$7.155M
YoY Change 70.51% -508.39%
Net Earnings / Revenue
Basic Earnings Per Share -$0.44 -$0.51
Diluted Earnings Per Share -$436.9K -$0.51
COMMON SHARES
Basic Shares Outstanding 27.80M 14.10M
Diluted Shares Outstanding 27.82M 14.10M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $98.67M $50.64M
YoY Change 94.85% 1.68%
Cash & Equivalents $8.324M $12.59M
Short-Term Investments $90.34M $38.05M
Other Short-Term Assets $4.025M $1.400M
YoY Change 187.5% 180.0%
Inventory
Prepaid Expenses $1.408M
Receivables
Other Receivables $89.00K
Total Short-Term Assets $103.1M $52.10M
YoY Change 97.92% 3.37%
LONG-TERM ASSETS
Property, Plant & Equipment $1.483M $2.800M
YoY Change -47.04% -28.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $176.0K $234.0K
YoY Change -24.79% 134.0%
Total Long-Term Assets $1.659M $3.028M
YoY Change -45.21% -24.3%
TOTAL ASSETS
Total Short-Term Assets $103.1M $52.10M
Total Long-Term Assets $1.659M $3.028M
Total Assets $104.8M $55.13M
YoY Change 90.06% 1.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.563M $1.161M
YoY Change 34.63% 65.86%
Accrued Expenses $4.706M $2.400M
YoY Change 96.08% -11.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.269M $4.500M
YoY Change 39.31% -56.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $133.0K $1.100M
YoY Change -87.91% -45.0%
Total Long-Term Liabilities $133.0K $1.100M
YoY Change -87.91% -45.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.269M $4.500M
Total Long-Term Liabilities $133.0K $1.100M
Total Liabilities $6.226M $5.400M
YoY Change 15.3% -56.1%
SHAREHOLDERS EQUITY
Retained Earnings -$384.4M -$345.7M
YoY Change 11.2%
Common Stock $16.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $98.55M $49.70M
YoY Change
Total Liabilities & Shareholders Equity $104.8M $55.13M
YoY Change 90.06% 1.25%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$12.20M -$7.155M
YoY Change 70.51% -508.39%
Depreciation, Depletion And Amortization $81.00K $121.0K
YoY Change -33.06% -22.93%
Cash From Operating Activities -$10.12M -$5.827M
YoY Change 73.66% -383.14%
INVESTING ACTIVITIES
Capital Expenditures -$43.00K $17.00K
YoY Change -352.94% -89.76%
Acquisitions
YoY Change
Other Investing Activities $14.67M -$23.38M
YoY Change -162.74% -302.07%
Cash From Investing Activities $14.63M -$23.40M
YoY Change -162.52% -305.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.481M 24.86M
YoY Change -94.04% 48.14%
NET CHANGE
Cash From Operating Activities -10.12M -5.827M
Cash From Investing Activities 14.63M -23.40M
Cash From Financing Activities 1.481M 24.86M
Net Change In Cash 5.988M -4.365M
YoY Change -237.18% -114.43%
FREE CASH FLOW
Cash From Operating Activities -$10.12M -$5.827M
Capital Expenditures -$43.00K $17.00K
Free Cash Flow -$10.08M -$5.844M
YoY Change 72.42% -408.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8896000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2686000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
224000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
47000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12154000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-7155000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12153000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-12650000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-7169000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-4000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12649000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7165000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109126000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1480000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
417000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
98374000
CY2021Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
9621000
CY2021Q1 life Issuance Of Common Stock From Committed Purchase Agreement Net Of Offering Costs
IssuanceOfCommonStockFromCommittedPurchaseAgreementNetOfOfferingCosts
15236000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
360000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-7155000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
49532000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
81000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
417000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
217000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
176000
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-9000
CY2021Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1950000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-395000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-204000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
105788000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
213000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1521000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-233000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
14500000
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
169000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14626000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1000
CY2021Q1 life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
9621000
CY2021Q1 life Proceeds From Issuance Of Common Stock Through Committed Purchase Agreement Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughCommittedPurchaseAgreementNetOfOfferingCosts
15236000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1481000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5988000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2336000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
105575000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
90342000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12200000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-384400000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.75%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure for these items in our condensed consolidated financial statements and accompanying notes. The most significant estimates in our condensed consolidated financial statements relate to clinical trial and research and development expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p>
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1839969
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
913668
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
91051000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
709000
CY2020Q1 life Upfront Payment Received
UpfrontPaymentReceived
8000000.0
CY2021Q1 life Milestone Payment Received
MilestonePaymentReceived
2000000.0
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
799000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
404000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
58000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1145000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1012000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
133000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2021Q1 life Commission Rate Equal To Gross Proceeds1
CommissionRateEqualToGrossProceeds1
0.030
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2223880
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1412550
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
331912
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.47
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
259
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.77
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
5477
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.89
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1738726
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.79
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
417000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
360000

Files In Submission

Name View Source Status
0001564590-22-019293-index-headers.html Edgar Link pending
0001564590-22-019293-index.html Edgar Link pending
0001564590-22-019293.txt Edgar Link pending
0001564590-22-019293-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
life-10q_20220331.htm Edgar Link pending
life-10q_20220331_htm.xml Edgar Link completed
life-20220331.xsd Edgar Link pending
life-20220331_cal.xml Edgar Link unprocessable
life-20220331_def.xml Edgar Link unprocessable
life-20220331_lab.xml Edgar Link unprocessable
life-20220331_pre.xml Edgar Link unprocessable
life-ex103_191.htm Edgar Link pending
life-ex104_190.htm Edgar Link pending
life-ex311_7.htm Edgar Link pending
life-ex312_6.htm Edgar Link pending
life-ex321_8.htm Edgar Link pending
life-ex322_9.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending